Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.35 |
| ▸ | CDK9 | P50750 | 9/20 | 0.35 |
| ▸ | CDK7 | P50613 | 3/20 | 0.35 |
| ▸ | CCNH | P51946 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.33 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CCND1 | P24385 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484514 | 0.80 | DGAT1 (0.36) | PIK3CDPIK3R1CCNT1CDK9CDK7 | |
| SCHEMBL14564413 | 0.79 | KCNN3 (0.40) | PIK3CDPIK3R1CCNT1CDK9CDK7 | |
| SCHEMBL2034177 | 0.74 | CDK9 (0.52) | CCNT1CDK9CDK7CCNHCDK4 | |
| SCHEMBL18878995 | 0.73 | MKNK1 (0.49) | DGAT1 | |
| SCHEMBL4572140 | 0.72 | DGAT1 (0.37) | DGAT1DPP4PDE10A | |
| SCHEMBL13769278 | 0.72 | PDE2A (0.46) | CCNT1CDK9CDK7CCNHKCNN3 | |
| SCHEMBL22971391 | 0.71 | KCNH2 (0.38) | DPP4 | |
| SCHEMBL18879006 | 0.71 | DGAT1 (0.33) | DGAT1PDE10A | |
| SCHEMBL1537948 | 0.71 | ALDH1A1 (0.45) | PDE10A | |
| SCHEMBL14158199 | 0.71 | PDE10A (0.61) | CCNT1CDK9CDK7CCNHKCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103279-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | Eli Lilly and Company (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3140296-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-0880523-B1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | CRHR1, CRHR2, CRH | PIK3CD 1660/4885PIK3R1 1381/4885CCNT1 1317/4885 |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | PIK3CD 1622/4885PIK3R1 2464/4885CCNT1 1603/4885 |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, OPRL1 | PIK3CD 2184/4885PIK3R1 1691/4885CCNT1 1023/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | PIK3CD 807/4885PIK3R1 559/4885CCNT1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.